A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia

Documenti analoghi

• Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3‐tyrosine kinase domain mutations: Prognostic implications of NPM1 co‐mutation
  di: Sankalp Arora, et al.
  Pubblicazione: (2025)
• Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
  di: Wei‐Ying Jen, et al.
  Pubblicazione: (2024)
• Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies
  di: Wei‐Ying Jen, et al.
  Pubblicazione: (2025)
• A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens
  di: Hagop M. Kantarjian, et al.
  Pubblicazione: (2025)
• Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications
  di: Tareq Abuasab, et al.
  Pubblicazione: (2024)